The activities of non-selective TKIs in HER2-mutant NSCLC patients yield moderate or even disappointing results, though sporadic responses have been reported as HER2 mutation location could affect the drug binding affinity. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.